Vaccines against Arthropods and Arthropod-Borne Pathogens

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 8435

Special Issue Editors


E-Mail Website
Guest Editor
Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain
Interests: anti-arthropod vaccines; transmission blocking vaccines; vector-host interactions; “omics” technologies; nanotechnologies; host immune responses; tick salivary and hidden components

E-Mail Website
Guest Editor
Facultad de Ciencias Naturales, Universidad Autónoma de Querétaro, Avenida de las Ciencias S/N, C.P. 76230, Juriquilla, Queretaro, Mexico
Interests: control of animal ectoparasites; anti-tick vaccines; vector-borne pathogens; emerging diseases; one health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Arthropods and arthropod-borne pathogens constantly threaten the health of humans, domestic animals, and wildlife. A geographical expansion of arthropods is occurring due to global warming, deforestation, and increase in reservoir population, animal hosts, and human outdoor activities. It is expected that this expansion will continue increasing, bringing with it an increase in the emergence and prevalence of arthropod-borne diseases. A One Health approach including arthropod correct management and control is urgently needed to prevent future outbreaks. Prevention of arthropods and arthropod-borne diseases through novel vaccination strategies and methods is perhaps the most suitable choice in the post COVID-19 vaccinomics era. 

The aim of this Special Issue is to compile relevant original scientific papers, opinion letters, and reviews on the most recent advances in developing vaccines against arthropods and arthropod-borne pathogen vaccines. Submitted papers may include discovery research, proof of concept, and vaccination trials in controlled and natural conditions. This information will reinforce the potential of immunization as a mean. Furthermore, the published advances would be included as part of One Health intervention approach to manage potential public and animal health threats coming from several unexpected areas.

Dr. Raúl Manzano-Román
Dr. Consuelo Almazán
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel vaccine candidates
  • nanovaccines
  • transmission-blocking vaccines
  • anti-microbiota vaccines
  • arthropod–host–pathogen interactions
  • host and vector immunity
  • pathogen-derived antigens
  • vaccination trials
  • arthropod vectors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1296 KiB  
Article
Long-Term Protective Immunity against Ehrlichia chaffeensis Infection Induced by a Genetically Modified Live Vaccine
by Swetha Madesh, Jodi McGill, Deborah C. Jaworski, Jonathan Ferm, Huitao Liu, Shawna Fitzwater, Paidashe Hove, Dominica Ferm, Arathy Nair, Cheyenne A. Knox, Kimia Alizadeh, Ashley Thackrah and Roman R. Ganta
Vaccines 2024, 12(8), 903; https://doi.org/10.3390/vaccines12080903 - 9 Aug 2024
Viewed by 757
Abstract
Human monocytic ehrlichiosis, an emerging tick-borne disease, is caused by Ehrlichia chaffeensis. Infections with the pathogen are also common in the canine host. Our previous studies demonstrated that functional disruption within the E. chaffeensis phage head-to-tail connector protein gene results in bacterial [...] Read more.
Human monocytic ehrlichiosis, an emerging tick-borne disease, is caused by Ehrlichia chaffeensis. Infections with the pathogen are also common in the canine host. Our previous studies demonstrated that functional disruption within the E. chaffeensis phage head-to-tail connector protein gene results in bacterial attenuation, creating a modified live attenuated vaccine (MLAV). The MLAV confers protective immunity against intravenous and tick transmission challenges one month following vaccination. In this study, we evaluated the duration of MLAV protection. Dogs vaccinated with the MLAV were challenged with wild-type E. chaffeensis via intravenous infection at 4-, 8-, and 12-months post-vaccination. Immunized dogs rapidly cleared the wild-type pathogen infection and tested positive for bacteremia less frequently than unvaccinated controls. While immune responses varied among dogs, vaccinees consistently mounted IgG and CD4+ T-cell responses specific to E. chaffeensis throughout the assessment period. Our findings demonstrate that MLAV-mediated immune protection persists for at least one year against wild-type bacterial infection, marking a major advancement in combating this serious tick-borne disease. The data presented here serve as the foundation for further studies, elucidating the molecular mechanisms underlying virulence and vaccine development and aiding in preventing the diseases caused by E. chaffeensis and other tick-borne rickettsial pathogens. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

19 pages, 1140 KiB  
Article
A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity
by Nichole D. Salinas, Rui Ma, Holly McAleese, Tarik Ouahes, Carole A. Long, Kazutoyo Miura, Lynn E. Lambert and Niraj H. Tolia
Vaccines 2024, 12(5), 546; https://doi.org/10.3390/vaccines12050546 - 16 May 2024
Viewed by 1229
Abstract
Malaria is caused by eukaryotic protozoan parasites of the genus Plasmodium. There are 249 million new cases and 608,000 deaths annually, and new interventions are desperately needed. Malaria vaccines can be divided into three categories: liver stage, blood stage, or transmission-blocking vaccines. [...] Read more.
Malaria is caused by eukaryotic protozoan parasites of the genus Plasmodium. There are 249 million new cases and 608,000 deaths annually, and new interventions are desperately needed. Malaria vaccines can be divided into three categories: liver stage, blood stage, or transmission-blocking vaccines. Transmission-blocking vaccines prevent the transmission of disease by the mosquito vector from one human to another. Pfs230 is one of the leading transmission-blocking vaccine antigens for malaria. Here, we describe the development of a 24-copy self-assembling nanoparticle vaccine comprising domain 1 of Pfs230 genetically fused to H. pylori ferritin. The single-component Pfs230D1-ferritin construct forms a stable and homogenous 24-copy nanoparticle with good production yields. The nanoparticle is highly immunogenic, as two low-dose vaccinations of New Zealand White rabbits elicited a potent and durable antibody response with high transmission-reducing activity when formulated in two distinct adjuvants suitable for translation to human use. This single-component 24-copy Pfs230D1-ferritin nanoparticle vaccine has the potential to improve production pipelines and the cost of manufacturing a potent and durable transmission-blocking vaccine for malaria control. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

11 pages, 1761 KiB  
Article
Immunization with Anaplasma centrale Msp2 HVRs Is Less Effective than the Live A. centrale Vaccine against Anaplasmosis
by Azeza Falghoush, Pei-Shin Ku and Kelly A. Brayton
Vaccines 2023, 11(10), 1544; https://doi.org/10.3390/vaccines11101544 - 29 Sep 2023
Viewed by 1414
Abstract
Bovine anaplasmosis, caused by Anaplasma marginale, is the most prevalent tick-transmitted pathogen of livestock globally. In many parts of the world, Anaplasma centrale, a related organism, is used as a live blood-borne vaccine as it causes either no or only a [...] Read more.
Bovine anaplasmosis, caused by Anaplasma marginale, is the most prevalent tick-transmitted pathogen of livestock globally. In many parts of the world, Anaplasma centrale, a related organism, is used as a live blood-borne vaccine as it causes either no or only a mild clinical disease. Anaplasma centrale does not prevent infection with A. marginale but does prevent acute disease. Anaplasma centrale is prohibited from being used in the U.S. due to the risk of transmitting emerging pathogens. Both of these organisms encode proteins known as major surface protein 2 (Msp2), which is the most immunodominant protein for the organism. Both organisms persist in their host by evading clearance, i.e., the adaptive immune response, by recombining the hypervariable region (HVR) of msp2 with pseudogene alleles. The study goal was to test whether the Msp2 HVRs encoded by A. centrale are a sufficient source of immune stimulation to provide the clinical protection exhibited by the blood-borne vaccine. Calves were inoculated with recombinantly expressed A. centrale HVRs. Control groups were inoculated with saponin or infected with the A. centrale live vaccine and compared with the test group. A Western blot analysis demonstrated that the HVR immunizations and A. centrale live vaccine stimulated an immune response. All animals in the study became infected upon challenge with A. marginale-infected ticks. The saponin-immunized control group had a high PPE (5.4%) and larger drops in PCVs (14.6%). As expected, the A. centrale-immunized animals were protected from acute disease with lower (0.6%) parasitemia and lower drops in PCV (8.6%). The HVR-immunized group had intermediate results that were not statistically significantly different from either the negative or positive controls. This suggests that the HVR immunogen does not fully recapitulate the protective capacity of the live vaccine. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

14 pages, 4384 KiB  
Article
Testing Efficacy of a Conserved Polypeptide from the Bm86 Protein against Rhipicephalus microplus in the Mexican Tropics
by Raymundo Coate, Miguel Ángel Alonso-Díaz, Moisés Martínez-Velázquez, Edgar Castro-Saines, Rubén Hernández-Ortiz and Rodolfo Lagunes-Quintanilla
Vaccines 2023, 11(7), 1267; https://doi.org/10.3390/vaccines11071267 - 21 Jul 2023
Cited by 2 | Viewed by 1536
Abstract
Rhipicephalus microplus economically impacts cattle production in tropical and subtropical countries. Application of acaricides constitutes the major control method; however, inadequate use has increased resistant tick populations, resulting in environmental and cattle product contamination. Anti-tick vaccines based on the Bm86 antigen are an [...] Read more.
Rhipicephalus microplus economically impacts cattle production in tropical and subtropical countries. Application of acaricides constitutes the major control method; however, inadequate use has increased resistant tick populations, resulting in environmental and cattle product contamination. Anti-tick vaccines based on the Bm86 antigen are an environmentally friendly, safe, and economically sustainable alternative for controlling R. microplus infestations. Nevertheless, variable efficacy has been experienced against different geographic tick strains. Herein, we evaluated the efficacy of a conserved polypeptide Bm86 derived from a Mexican R. microplus strain previously characterized. Twelve cows were assigned to three experimental groups and immunized with three doses of the polypeptide Bm86 (pBm86), adjuvant/saline alone, and Bm86 antigen (control +), respectively. Specific IgG antibody levels were measured by ELISA and confirmed by Western blot. In addition, the reproductive performance of naturally infested R. microplus was also determined. The more affected parameter was the adult female tick number, with a reduction of 44% by the pBm86 compared to the controls (p < 0.05), showing a vaccine efficacy of 58%. Anti-pBm86 IgG antibodies were immunogenic and capable of recognizing the native Bm86 protein in the eggs, larvae, and guts of R. microplus. The negative correlation between antibody levels and the reduction of naturally tick-infested cattle suggested that the effect of the polypeptide Bm86 was attributed to the antibody response in immunized cattle. In conclusion, the polypeptide Bm86 showed a specific immune response in cattle and conferred protection against R. microplus in a Mexican tropical region. These findings support further experiments with this antigen to demonstrate its effectiveness as a regional vaccine. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2143 KiB  
Review
Global Seroprevalence of Tick-Borne Encephalitis Antibodies in Humans, 1956–2022: A Literature Review and Meta-Analysis
by Patrick H. Kelly, Pingping Zhang, Gerhard Dobler, Kate Halsby, Frederick J. Angulo, Andreas Pilz, Harish Madhava and Jennifer C. Moïsi
Vaccines 2024, 12(8), 854; https://doi.org/10.3390/vaccines12080854 - 30 Jul 2024
Viewed by 875
Abstract
Despite the availability of tick-borne encephalitis (TBE) vaccines, the incidence of TBE is increasing. To understand the historical patterns of infection, we conducted a global meta-analysis of studies before December 2023 reporting human antibody prevalence against TBEV (TBE virus) among general or high-risk [...] Read more.
Despite the availability of tick-borne encephalitis (TBE) vaccines, the incidence of TBE is increasing. To understand the historical patterns of infection, we conducted a global meta-analysis of studies before December 2023 reporting human antibody prevalence against TBEV (TBE virus) among general or high-risk population groups stratified by country, collection year, serological method, and vaccination status. Pooled data were compared within groups over time by random-effects modeling. In total, 2403 articles were retrieved; 130 articles published since 1959 were included. Data were extracted from 96 general populations (117,620 participants) and 71 high-risk populations (53,986 participants) across 33 countries. Germany had the most population groups (21), and Poland had the most participants (44,688). Seven serological methods were used; conventional IgG/IgM ELISAs were the most common (44%). Four studies (1.7%) used NS1-ELISA serology. Between 1956–1991 and 1992–2022, anti-TBEV seroprevalence remained at ~2.75% across all population groups from “high-risk” areas (p = 0.458) but decreased within general populations (1.7% to 1%; p = 0.001) and high-risk populations (5.1% to 1.3%; p < 0.001), possibly due to differences in the study methodologies between periods. This global summary explores how serological methods can be used to assess TBE vaccination coverage and potential exposure to TBEV or measure TBE burden and highlights the need for standardized methodology when conducting TBE seroprevalence studies to compare across populations. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

15 pages, 1302 KiB  
Review
Inclusion of Anti-Tick Vaccines into an Integrated Tick Management Program in Mexico: A Public Policy Challenge
by Rodrigo Rosario-Cruz, Delia Inés Domínguez-García and Consuelo Almazán
Vaccines 2024, 12(4), 403; https://doi.org/10.3390/vaccines12040403 - 10 Apr 2024
Viewed by 1251
Abstract
Acaricides are the most widely used method to control the cattle tick Rhipicephalus microplus. However, its use increases production costs, contaminates food and the environment, and directly affects animal and human health. The intensive use of chemical control has resulted in the [...] Read more.
Acaricides are the most widely used method to control the cattle tick Rhipicephalus microplus. However, its use increases production costs, contaminates food and the environment, and directly affects animal and human health. The intensive use of chemical control has resulted in the selection of genes associated with resistance to acaricides, and consumers are increasingly less tolerant of food contamination. This scenario has increased the interest of different research groups around the world for anti-tick vaccine development, in order to reduce the environmental impact, the presence of residues in food, and the harmful effects on animal and human health. There is enough evidence that vaccination with tick antigens induces protection against tick infestations, reducing tick populations and acaricide treatments. Despite the need for an anti-tick vaccine in Mexico, vaccination against ticks has been limited to one vaccine that is used in some regions. The aim of this review is to contribute to the discussion on tick control issues and provide a reference for readers interested in the importance of using anti-tick vaccines encouraging concerted action on the part of Mexican animal health authorities, livestock organizations, cattle producers, and academics. Therefore, it is suggested that an anti-tick vaccine should be included as a part of an integrated tick management program in Mexico. Full article
(This article belongs to the Special Issue Vaccines against Arthropods and Arthropod-Borne Pathogens)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Current status of vaccination against Rhipicephalus microplus in Mexico: A public Policy Challenge
Authors: Rodrigo Rosario-Cruz; Consuelo Almazán García; Delia Inés Domínguez-García
Affiliation: 1Natural Sciences College, Biotechnology in Health and Environmental Sciences Research Laboratory, Autónomous Guerrero State University, Chilpancingo, Guerrero C.P. 39070. México. 2Immunology and Vaccines Laboratory, College of Natural Sciences, Autonomous University of Queretaro. Queretaro, Mexico.
Abstract: Arthropods occupy 80% of the known species in the animal kingdom and are evolutionary successful organisms. Some of these species of arthropods compete for human food sources, as parasites, and are vectors of parasites, bacterial, and viral pathogens. Ticks are a major concern to human health and livestock worldwide, being responsible for economic losses that go beyond billions of US dollars per year. The most used method for tick control relies on the use of acaricides, which increases production costs, contaminate food and environment, and directly affects animal and human health. In addition, ticks have developed a broad resistance to acaricides and chemical contamination of meat, milk, and other animal sub-products is no longer tolerated by consumers. There is abundant evidence that vaccination with identified protein antigens induces immunity to protect against tick infestations. This scenario has stimulated the interest of different groups of scientists around the world, who have moved on to the field of anti-tick vaccine research. So far, more than 20 antigens have already been tested in vaccination trials against the cattle tick Rhipicephalus microplus, with significant results on tick reduction. However, in spite of the need of an anti-tick vaccine, the Mexican market has been restricted to the Bm86-based vaccine, and only to certain geographical regions. Considering the amount of identified and tested antigens, tick vaccines are under utilized as a tick control method. The aim of this review is to explore the current status of the cattle-tick integrated management, research actions, the availability of anti-tick vaccines to cattle producers, and the concerted participation of livestock associations, research institutions, private industry and animal health authorities.

Title: Tick Vaccines: new targets and future directions
Authors: Juan Mosqueda*, Martina Perez-Soria, Ilwicatzin Guerrero-Solorio, Aldo Josue Pavón-Rocha, Rodrigo Morales-García, Ivan Corona-Guerrero, Diego Josimar Hernández-Silva and Consuelo Almazán
Affiliation: Immunology and Vaccines Laboratory, College of Natural Sciences, Autonomous University of Queretaro. Queretaro, Mexico.
Abstract: Ticks are the ectoparasites that cause the most damage to the veterinary industry. Because of their hematophagous habits, ticks consume significant amounts of blood, causing debilitating and immunosuppressive effects. In addition, ticks are the major transmitters of pathogens, including viruses, bacteria, and protozoa. Tick infestations are controlled with acaricides; however, disadvantages of their use including the growing resistance of ticks to ixodicides, the negative impact on human and animal health, and the ecological damage on the environment, force the use of new sustainable alternatives such as immune control through vaccination. Although commercial vaccines against the most important cattle tick, Rhipicephalus microplus have been developed, vaccines against other tick species do not exist. In addition, vaccines based on other antigens besides Bm86, an antigen from the surface of tick midgut, have not been developed. This review will describe the key aspects of the immune response required for tick vaccine antigens and the reported findings for new tick vaccine antigens. The importance of using methodologies like reverse vaccinology and immunobioinformatics to identify and evaluate new tick antigens isolated from intestine, salivary gland, and ovary; as well as antigens involved in the suppression of the immune response such as antimicrobial peptides (hemocidins, microplusins and defensins), pattern recognition receptors, redox metabolism, complement-like proteins, antiviral RNAi responses and regulated cell-death will be reviewed. We will explore new approaches to vaccine development like the so-called “multi-epitopic” vaccine and vaccines based on tick microbiota. Finally, new strategies to develop effective vaccines against different tick species such as R. microplus, R. annulatus, R. linae, Amblyomma spp. and Ixodes spp. will be addressed.

Title: A perspective on the use of plant-made vaccines to combat ticks of veterinary importance
Authors: Carlos Angulo; Consuelo Almazan; Elizabeth Monreal-Escalante; Abel Ramos-Vega
Affiliation: Immunology & Vaccinology Group, Centro de Investigaciones Biológicas del Noroeste (CIBNOR), Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz 23096, Mexico
Abstract: Ticks are arthropods causing parasitosis in animals and some of them transmit microbial pathogens to animals and humans. Several vaccines have shown immunogenicity and protective efficacy against ticks in animal models and definitive hosts. However, only a commercial vaccine is available, which is based on a recombinant antigen. In this arena, plants offer three decades of research & development as a recombinant vaccine production host and delivery vehicle platform. Despite the experimental advances in plant-made vaccines to combat several parasitosis and infectious diseases, no vaccine prototype has been developed against ticks. This review brings a panorama of ticks of veterinary importance, recombinant vaccine experimental developments, plant-made vaccine platform, and perspectives on using this technology considering opportunities and limitations in the field.

Back to TopTop